BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 51,433 shares, a drop of 20.4% from the December 31st total of 64,583 shares. Currently, 3.5% of the company’s shares are sold short. Based on an average daily volume of 41,429 shares, the days-to-cover ratio is currently 1.2 days. Based on an average daily volume of 41,429 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.5% of the company’s shares are sold short.
BiomX Stock Down 18.9%
Shares of NYSEAMERICAN PHGE traded down $1.33 during mid-day trading on Friday, reaching $5.72. 210,266 shares of the company were exchanged, compared to its average volume of 2,909,394. BiomX has a 1 year low of $1.50 and a 1 year high of $22.06. The firm has a 50-day moving average of $3.21 and a 200 day moving average of $7.21. The stock has a market cap of $8.75 million, a price-to-earnings ratio of -0.22 and a beta of 1.60.
Analysts Set New Price Targets
Separately, HC Wainwright raised their price target on BiomX to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, BiomX currently has a consensus rating of “Buy” and an average target price of $26.00.
About BiomX
BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.
The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.
Read More
- Five stocks we like better than BiomX
- The day the gold market broke
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Gold’s getting scarce.
- Washington knows what’s coming. Do you?
- The Real Risk in Roth Conversions
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
